GLP-1 Market
LLY $1166.51 ▼ -1.4% NVO $38.06 ▼ -1.3% PFE $28.37 ▼ -0.1% VKTX $26.65 ▼ -6.0% KLRA $10.77 ▼ -4.9% GPCR $22.31 ▼ -6.7% RHHBY $53.77 ▼ -0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Azilsartan Kamedoxomil

Company
Baylor Research Institute
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Find a Clinical Trial Near Me

See recruiting studies for Azilsartan Kamedoxomil and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05498675

    Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

    Beijing Friendship Hospital 180 participants Est. completion 2027-06-30 1 site
    Other conditions: Sacubitril/Valsartan, Hypertension, Obesity
    View official trial listing →
  • Recruiting NCT NCT07683585

    Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention

    Not yet reported National Medical Research Center for Therapy and Preventive Medicine 207 participants Est. completion 2026-09 1 site
    Other conditions: Hypertension, Coronary Arterial Disease, Percutaneous Coronary Intervention
    View official trial listing →
  • Completed NCT NCT00362115

    Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

    Not yet reported Takeda 449 participants Est. completion 2006-12 54 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Terminated NCT NCT00376181

    Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Takeda 96 participants Est. completion 2007-05 73 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00591253

    Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

    Not yet reported Takeda 413 participants Est. completion 2009-04 64 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00591266

    Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

    Not yet reported Takeda 566 participants Est. completion 2009-04 50 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00591578

    Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

    Not yet reported Takeda 984 participants Est. completion 2010-03 88 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00591773

    Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

    Not yet reported Takeda 551 participants Est. completion 2009-03 46 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00695955

    One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

    Not yet reported Takeda 669 participants Est. completion 2010-05 41 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00696241

    Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

    Not yet reported Takeda 1275 participants Est. completion 2008-10 85 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00696384

    A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

    Not yet reported Takeda 418 participants Est. completion 2009-04 45 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00696436

    An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

    Not yet reported Takeda 1291 participants Est. completion 2009-08 131 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00759551

    Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

    Not yet reported Takeda 555 participants Est. completion 2005-06 Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00760214

    Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

    Not yet reported Takeda 885 participants Est. completion 2009-04 72 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00762736

    Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

    Not yet reported Takeda 704 participants Est. completion 2005-10 78 sites Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00818883

    Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

    Not yet reported Takeda 609 participants Est. completion 2009-11 53 sites Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT00846365

    Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

    Not yet reported Takeda 1085 participants Est. completion 2010-06 80 sites Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT00847626

    Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

    Not yet reported Takeda 1711 participants Est. completion 2010-07 99 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT00996281

    Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

    Not yet reported Takeda 837 participants Est. completion 2011-11 26 sites Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT01033071

    Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

    Not yet reported Takeda 1071 participants Est. completion 2010-11 94 sites Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Terminated NCT NCT01078376

    A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

    Not yet reported Takeda 29 participants Est. completion 2013-09 8 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Terminated NCT NCT01124656

    Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes

    Not yet reported Takeda 26 participants Est. completion 2007-05 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01289132

    Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

    Not yet reported Takeda 926 participants Est. completion 2008-07 Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT01309828

    Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

    Not yet reported Takeda 153 participants Est. completion 2012-10 53 sites Stand-alone
    Other conditions: Safety
    View official trial listing →
  • Completed NCT NCT01456169

    A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

    Not yet reported Takeda 507 participants Est. completion 2013-01 108 sites Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Terminated NCT NCT01496430

    Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

    Not yet reported Takeda 105 participants Est. completion 2013-05 68 sites Stand-alone
    Other conditions: Hypertension, Diabetes
    View official trial listing →
  • Completed NCT NCT01609959

    New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

    Not yet reported Nara Medical University 70 participants Est. completion 2013-10 1 site
    Other conditions: Hypertension
    View official trial listing →
  • Status unknown NCT NCT01715584

    Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics

    Not yet reported London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 80 participants Est. completion 2019-12-31 1 site
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT01762501

    Azilsartan Circadian and Sleep Pressure

    Not yet reported Sogo Rinsho Médéfi Co., Ltd. 957 participants Est. completion 2013-12 92 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT01774591

    Effect of Azilsartan on Aldosterone in Postmenopausal Females

    Not yet reported University of Chicago 21 participants Est. completion 2016-01 1 site
    Other conditions: Hypertension
    View official trial listing →
  • Status unknown NCT NCT01985152

    A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers

    Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 62 participants 1 site Stand-alone
    Other conditions: Health
    View official trial listing →
  • Completed NCT NCT02072330

    Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

    Not yet reported, Not yet reported Takeda 353 participants Est. completion 2013-12 13 sites
    Other conditions: Grade I or II Essential Hypertension
    View official trial listing →
  • Completed NCT NCT02079805

    A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

    Not yet reported Takeda 33 participants Est. completion 2016-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02092025

    Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

    Takeda 3437 participants Est. completion 2016-01-15 2 sites
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02100319

    Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

    Takeda 387 participants Est. completion 2016-02-29 2 sites
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02181816

    Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey "Long-term Use Survey"

    Takeda 1090 participants Est. completion 2017-01-31 2 sites
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02203916

    Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

    Not yet reported Takeda 328 participants Est. completion 2016-02 15 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Status unknown NCT NCT02235519

    Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients

    Not yet reported, Not yet reported Hospital General de México Dr. Eduardo Liceaga 300 participants Est. completion 2015-06 1 site
    Type 2 diabetes Other conditions: Hypertension, Obesity
    View official trial listing →
  • Completed NCT NCT02235909

    An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

    Not yet reported Arbor Pharmaceuticals, Inc. 377 participants Est. completion 2019-11-11 69 sites Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02277691

    A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

    Not yet reported Takeda 341 participants Est. completion 2016-04-25 38 sites
    Other conditions: Essential Hypertension
    View official trial listing →
  • Withdrawn NCT NCT02400775

    A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

    Not yet reported Takeda Est. completion 2016-04 1 site Stand-alone
    Other conditions: Essential Hypertension With Stable Angina and Dyslipidemia
    View official trial listing →
  • Completed NCT NCT02401464

    A Bioequivalence Study of TAK-536 Pediatric Formulation

    Not yet reported Takeda 52 participants Est. completion 2015-05 1 site
    Other conditions: Japanese Healthy Adult Males
    View official trial listing →
  • Status unknown NCT NCT02407210

    Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 304 participants 1 site Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT02451150

    A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

    Not yet reported Takeda 6 participants Est. completion 2015-09 3 sites Stand-alone
    Other conditions: Pediatric Hypertension
    View official trial listing →
  • Completed NCT NCT02480764

    Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

    Not yet reported Takeda 612 participants Est. completion 2017-10-13 30 sites Stand-alone
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT02517866

    Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

    Not yet reported Takeda 380 participants Est. completion 2016-11-25 11 sites Stand-alone
    Type 2 diabetes Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT02541669

    A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants

    Not yet reported Takeda 64 participants Est. completion 2017-03-17 1 site
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Completed NCT NCT02609490

    Azilsartan in Chinese Patients With Mild and Moderate Hypertension

    Not yet reported Lee's Pharmaceutical Limited 304 participants Est. completion 2018-08 1 site Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02756819

    International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

    Takeda 1945 participants Est. completion 2018-05-08 66 sites
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02786082

    Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers

    Not yet reported Lee's Pharmaceutical Limited 29 participants Est. completion 2017-11-30 Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Completed NCT NCT02791438

    A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

    Not yet reported Takeda 27 participants Est. completion 2019-06-04 30 sites Stand-alone
    Other conditions: Pediatric Hypertension
    View official trial listing →
  • Completed NCT NCT03006796

    Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.

    Russian Heart Failure Society 94 participants Est. completion 2020-03-31 1 site
    Other conditions: Arterial Hypertension
    View official trial listing →
  • Completed NCT NCT03042299

    A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

    Not yet reported Takeda 14 participants Est. completion 2017-03-11 1 site
    Other conditions: Japanese Healthy Adult Male Participants
    View official trial listing →
  • Completed NCT NCT03434977

    A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation

    Not yet reported Takeda 12 participants Est. completion 2018-03-11 1 site
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03539627

    Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.

    Research Institute for Complex Problems of Cardiovascular Diseases, Russia 184 participants Est. completion 2022-04-29 1 site
    Other conditions: Arterial Hypertension, Diabetes Mellitus, Stable Chronic Angina
    View official trial listing →
  • Completed NCT NCT03652792

    Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers

    Not yet reported Lee's Pharmaceutical Limited 60 participants Est. completion 2018-07-05 1 site Stand-alone
    Other conditions: Bioequivalence of Two Azilsartan Formulations
    View official trial listing →
  • Completed NCT NCT04467931

    ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    University of Utah 22213 participants Est. completion 2020-12-31 1 site
    Other conditions: Hypertension, COVID
    View official trial listing →
  • Completed NCT NCT04470817

    A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

    Celltrion Pharm, Inc. 3438 participants Est. completion 2023-05-25 1 site
    Other conditions: Essential Hypertension
    View official trial listing →
  • Completed NCT NCT04470830

    A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea

    Celltrion Pharm, Inc. 718 participants Est. completion 2023-05-25 1 site
    Other conditions: Essential Hypertension
    View official trial listing →
  • Terminated NCT NCT04606563

    Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

    Not yet reported University of British Columbia 341 participants Est. completion 2022-04-22 13 sites Stand-alone
    Other conditions: Covid19, SARS-CoV Infection
    View official trial listing →
  • Completed NCT NCT04668157

    A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure

    Not yet reported Takeda 10 participants Est. completion 2023-12-28 19 sites
    Other conditions: Hypertension
    View official trial listing →
  • Status unknown NCT NCT04743063

    Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

    Brigham and Women's Hospital 40000 participants Est. completion 2022-12-31 1 site
    Heart failure Other conditions: Frailty
    View official trial listing →
  • Completed NCT NCT05002244

    A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers

    Not yet reported Celltrion 37 participants Est. completion 2021-09-13 1 site Stand-alone
    Other conditions: Health, Subjective
    View official trial listing →
  • Completed NCT NCT05107960

    A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure

    Takeda 5 participants Est. completion 2024-08-31 1 site
    Other conditions: Hypertension
    View official trial listing →
  • Status unknown NCT NCT05753696

    Azilsartan in Patients With Diabetic Kidney Disease and Hypertension

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 106 participants Est. completion 2024-12-30 1 site Stand-alone
    Chronic kidney disease Other conditions: Proteinuria, Kidney Dysfunction, Blood Pressure
    View official trial listing →
  • Status unknown NCT NCT05841654

    Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension

    Not yet reported Beijing Tsinghua Chang Gung Hospital 400 participants Est. completion 2025-10-01 1 site Stand-alone
    Other conditions: Hypertension, Atrial Fibrillation
    View official trial listing →
  • Status unknown NCT NCT05947448

    Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

    Hasten Biopharmaceutical Co., Ltd. 1215 participants Est. completion 2025-12-31 1 site
    Other conditions: Essential Hypertension
    View official trial listing →
  • Status unknown NCT NCT06618079

    Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B

    Not yet reported Huons Co., Ltd. 46 participants Est. completion 2024-10-01 1 site Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Not yet recruiting NCT NCT06990204

    Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)

    Not yet reported Gedeon Richter Plc. 56 participants Est. completion 2025-07-01 1 site Stand-alone
    Other conditions: Hypertension
    View official trial listing →
  • Not yet recruiting NCT NCT07262710

    Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

    First Teaching Hospital of Tianjin University of Traditional Chinese Medicine 13656 participants Est. completion 2026-08-19
    Cardiovascular disease
    View official trial listing →
  • Enrolling by invitation NCT NCT07547878

    Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

    Not yet reported Baylor Research Institute 64 participants Est. completion 2029-03-31 1 site
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Azilsartan Kamedoxomil, Edarbi, Azilsartan

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.